Healios KK Delays MultiStem ARDS Therapy Agreement
Company Announcements

Healios KK Delays MultiStem ARDS Therapy Agreement

Healios KK (JP:4593) has released an update.

Healios KK has postponed finalizing its development and commercialization agreement with Nobelpharma for MultiStem, a stem cell therapy for ARDS, from September 2024 to January 2025. This delay will allow further discussions in light of recent developments, including a positive Phase 2 study in Japan and ongoing preparations for a global Phase 3 trial. The company asserts that this rescheduling will not affect its consolidated financial results for the fiscal year ending December 31, 2024.

For further insights into JP:4593 stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App